Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OcuCell
Zug, Zug, Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
OcuCell AG was a Swiss biotechnology company focused on developing regenerative cell therapies for ophthalmic diseases, specifically Age-related Macular Degeneration (AMD). The company's lead approach involved the transplantation of autologous iris pigment epithelial (IPE) cells to replace damaged retinal pigment epithelial (RPE) cells in the eye. OcuCell conducted clinical trials in collaboration with the University of Leipzig to evaluate the safety and efficacy of this surgical cell therapy. Despite pioneering early efforts in ocular regenerative medicine, the company faced financial challenges and entered liquidation in the mid-2000s.
- Therapeutic areas
- Ophthalmology
- Modalities
- Cell therapyAutologous cell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on OcuCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OcuCell.